GLP1R and obesity due to melanocortin 4 receptor deficiency: While our findings are broadly consistent with a recent nationwide analysis of GLP-1 RA use and cancer risk in individuals with obesity [26], our study provides additional insights by focusing on a clearly defined early exposure period within a diabetes-specific population.